Eton Pharmaceuticals, Inc. (ETON) is a Biotechnology company in the Healthcare sector, currently trading at $26.97. It has a SharesGrow Score of 38/100, indicating a weak investment profile with 1 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of ETON = $381.58 (+1314.8% from the current price, the stock appears undervalued). Analyst consensus target is ETON = $25 (-7.3% upside).
Valuation: ETON trades at a trailing Price-to-Earnings (P/E) of -154.5 (S&P 500 average ~25).
Financials: revenue is $80M, +59%/yr average growth. Net income is $5M (loss), growing at -79.5%/yr. Net profit margin is -5.8% (negative). Gross margin is 53.5% (-13.9 pp trend).
Balance sheet: total debt is $31M against $26M equity (Debt-to-Equity (D/E) ratio 1.19, moderate). Current ratio is 1.57 (strong liquidity). Debt-to-assets is 33.7%. Total assets: $92M.
Analyst outlook: 6 / 6 analysts rate ETON as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 35/100 (Fail), Growth 58/100 (Partial), Past 0/100 (Fail), Health 50/100 (Partial), Moat 41/100 (Fail), Future 74/100 (Pass), Income 10/100 (Fail).
